Boston Scientific
Advancing science for life™

SYNTAX II
Clinical Trial

The Path to Modern PCI with a Personalized Data-Driven Approach

The SYNTAX II trial evaluated patients with three-vessel disease, and utilizing physiology, IVUS, state-of-the art tools and techniques, produced CABG-like outcomes out to 5 years



*The safety and effectiveness of the SYNERGY Stent has not been established in patients with three-vessel disease or chronic total occlusions.

Boston Scientific is the only company that has a minimally invasive complete revascularization portfolio to address these needs for patients.

Physiological Assessment

Physiologic assessment occured in **98%** of patients which contributed to:

46% reduction of three-vessel ischemic disease diagnosis compared to when no physiology was used

1.4 less lesions per patient treated

Changed three-vessel disease diagnoses in nearly 2/3 of patients

IVUS Guidance

IVUS-guided treatment is a core tenet of the updated PCI treatment algorithm

IVUS-guided stent optimization contributed to reduced adverse events.



IVUS use occurred in **84.1%** of patients

IVUS usage post stent implantation led to further optimization of the stented lesion in **30.2%** of cases

Tools & Techniques

The results from SYNTAX II prove that multivessel disease PCI patients can experience excellent, CABG-like outcomes out to five years. Despite case complexity, SYNTAX II, when compared to SYNTAX I PCI, shows statistically significant risk reduction in MACCE and ST due to the modern approach.

21.5% MACCE* at 5-years

41% relative risk reduction

75% relative risk reduction

1.4% ARC Def. ST Rate at 5-years

*MACCE is a composite of all-cause death, stroke, MI, and any repeat revascularization

Complete revascularization techniques demonstrated a significantly higher CTO procedural success rate.

87% success rate

34% increase in CTO success from SYNTAX I

Contact a Boston Scientific representative today for more information.

Boston Scientific

Advancing science for life™

Interventional Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information contact customer service at 1.888.272.1001.

IC-1123312-AA

The SYNTAX II Trial studied the SYNERGY Bioabsorbable Polymer Stent in patients with either CTO or three vessel disease. The SYNTAX I trial studied the TAXUS Express2 drug eluting stent in patients with either Left Main or three vessel disease.

1. Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal. 2017;38(42):3124-3134.